The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 04, 2023

Filed:

Dec. 05, 2019
Applicant:

Hoffmann-la Roche Inc., Little Falls, NJ (US);

Inventors:

Michael Gerg, Munich, DE;

Dieter Heindl, Paehl, DE;

Gerhard Niederfellner, Oberhausen, DE;

Wolfgang Schaefer, Mannheim, DE;

Michael Schraeml, Penzberg, DE;

Michael Tacke, Munich, DE;

Assignee:

Hoffmann-La Roche Inc., Little Falls, NJ (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/46 (2006.01); C07K 16/18 (2006.01); C07K 16/00 (2006.01); C07K 16/28 (2006.01); C07K 16/32 (2006.01); G01N 33/573 (2006.01); G01N 33/68 (2006.01); A61K 47/68 (2017.01);
U.S. Cl.
CPC ...
C07K 16/46 (2013.01); A61K 47/6889 (2017.08); C07K 16/00 (2013.01); C07K 16/18 (2013.01); C07K 16/2863 (2013.01); C07K 16/32 (2013.01); G01N 33/573 (2013.01); G01N 33/6863 (2013.01); C07K 2317/24 (2013.01); C07K 2317/30 (2013.01); C07K 2317/34 (2013.01); C07K 2317/55 (2013.01); C07K 2317/92 (2013.01);
Abstract

Herein is reported a polypeptide-polynucleotide-complex as therapeutic agent and its use as tool for the targeted delivery of an effector moiety. The polynucleotide part of the complex is essentially resistant to proteolytic and enzymatic degradation in vivo. Additionally the polypeptide part specifically binds to a compound or structure such as a tissue or organ, a process or a disease. Thus, one aspect as reported herein is a polypeptide-polynucleotide-complex comprising a) a polypeptide specifically binding to a target and conjugated to a first member of a binding pair, b) a polynucleotide linker conjugated at its first terminus to the second member of the binding pair, and c) an effector moiety conjugated to a polynucleotide that is complementary to at least a part of the polynucleotide linker.


Find Patent Forward Citations

Loading…